Genzyme raises $141 million for general division
This article was originally published in Clinica
US healthcare company Genzyme raised $141 million net from the recent offering of nearly 2.9 million shares in its general division priced at $51.25 each. This followed a smaller offering a few weeks earlier of shares in Genzyme's other division, Genzyme Tissue Repair (see Clinica No 676, p 12).
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.